Mogamulizumab + Nivolumab
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer, Esophageal Cancer, Lung Cancer, Renal Cancer, Oral Cancer
Trial Timeline
Mar 1, 2016 → Mar 1, 2020
NCT ID
NCT02946671About Mogamulizumab + Nivolumab
Mogamulizumab + Nivolumab is a phase 1 stage product being developed by Kyowa Kirin for Gastric Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02946671. Target conditions include Gastric Cancer, Esophageal Cancer, Lung Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Cancer were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02946671 | Phase 1 | Completed |
| NCT02705105 | Phase 1/2 | Completed |
Competing Products
20 competing products in Gastric Cancer